Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Portela^® (relfovetmab), a new monoclonal antibody (mAb) therapy intended for the alleviation of pain associated with osteoarthritis (OA) in cats.

Portela Will Be First Long-Acting Anti-NGF mAb Therapy for Cats, If Approved
If approved, Portela will be the first long-acting anti-nerve growth factor (NGF) mAb therapy for cats and is designed to provide three months of osteoarthritis (OA) pain relief with a single injection. The product targets NGF, a key mediator of OA pain. The CVMP has recommended granting marketing authorization based on a positive benefit-risk balance of the safety and efficacy data submitted. In clinical trials, Portela was found to be well tolerated, including by cats identified with kidney disease at IRIS stage 1, 2 or 3¹, and demonstrated effectiveness in alleviating OA pain.

“The CVMP’s positive opinion for Portela represents a significant step forward in advancing feline pain management,” said Rob Polzer, Ph.D., Executive Vice President and President, Research and Development at Zoetis. “The long-acting antibody properties of Portela and its unique binding site to NGF will soon offer veterinarians and cat owners in the European Union a new option to alleviate pain associated with osteoarthritis, thereby helping to improve the quality of life for affected cats.”

OA as a Significant Unmet Medical Need
Osteoarthritis (OA) is a common, chronic and progressive joint disease characterized by the inflammation and breakdown of joints, leading to pain and mobility issues. Although the disease cannot be cured, much can be done to control the associated pain and improve quality of life. Though up to 40% of all cats have clinical signs of OA^{2 3}, these signs are often overlooked by pet owners, and as a result only 18% of affected cats are diagnosed with OA pain by veterinary professionals⁴. Identifying and treating OA pain is important because chronic pain has a negative impact on many aspects of a cat’s health. In addition to gait and movement, chronic pain impacts sleep, relationships, and cognition⁵. If approved, Portela will provide a convenient, long-acting therapy to reduce OA pain - particularly beneficial for cats that are difficult to medicate regularly.

Building on a Legacy of Innovation
Zoetis continues to advance care for animals around the globe with a robust pipeline fueled by lifecycle innovation, geographic expansion and disruptive innovation. If approved, Portela expands the company’s OA pain franchise and joins Solensia^® (frunevetmab) – an anti-NGF monoclonal antibody indicated for monthly alleviation of OA pain in cats. Approved in more than 40 countries, Solensia has been demonstrated to relieve pain and enhance the quality of life for cats with OA pain in clinical trials and now in over four years of real world use by veterinarians. As with all medicines, there are potential side effects. For Solensia, the most common (may affect up to 1 in 10 cats) are hair loss, dermatitis and itching; rare (may affect up to 1 in 1,000 cats) side effects are injection site reactions and skin lesions; and, very rare (may affect up to 1 in 10,000 cats) side effects are anaphylaxis.

“If approved, Portela will be a new, science-driven solution designed to support long-term comfort and mobility for cats—with the added benefit that pet owners only need to bring their cats in for an injection once every three months. This is a testament to the value we place at Zoetis on meaningful innovation in feline medicine, solving for the unmet needs of our feline patients and their families," said Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis. "Four years ago in the EU, we introduced the first monoclonal antibody therapy to control pain associated with OA in cats, and we look forward to providing veterinarians with another innovative tool to help them improve the quality of life for the animals in their care."

Next Steps Toward Launch
Based on the CVMP’s positive opinion, the European Commission is expected to issue a decision during the fourth quarter of 2025, and Zoetis anticipates making Portela commercially available in the European Union in 2026.

About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements which reflect the current views of Zoetis with respect to: our business plans or prospects; expectations regarding products, product approvals or licenses, products under development; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

ZTS-COR
ZTS-IR
ZTS-CA
ZTS-PS

1. IRIS stages of kidney disease. Accessed August 21, 2025. https://static1.squarespace.com/static/666b9ecb4064a156963b4162/t/66a6dbc90ca6986e1b5c06bd/1722211273243/2_IRIS_Staging_of_CKD_2023.pdf 
2. Enomoto M, Mantyh PW, Murrell J, Innes JF, Lascelles BDX. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet Rec. 2019;184(1):23.
3. L.I. Slingerland, H.A.W. Hazewinkel, B.P. Meij, Ph. Picavet, G. Voorhout, Cross-sectional study of the prevalence and clinical features of osteoarthritis in 100 cats. The Veterinary Journal, Volume 187, Issue 3, 2011, Pages 304-309.
4. Solensia Veterinarian A&U MR (MARC 2025)
5. Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250(8):71-78.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250912419265/en/

Media Contacts:

Jennifer Albano

862-399-0810 (o)

jennifer.albano@zoetis.com

Laura Panza

973-975-5176 (o)

laura.panza@zoetis.com

Investor Contacts:

Steve Frank

973-822-7141 (o)

steve.frank@zoetis.com

Nick Soonthornchai

973-443-2792 (o)

nick.soonthornchai@zoetis.com

Source: Zoetis Inc.